The Pharma Letter Podcast
Episodes
37 episodes
BenevolentAI CEO on the future of AI-led medicine
This week on The Pharma Letter Podcast, we’re joined by Kenneth Mulvany, founder and executive chair of BenevolentAI: one of the UK’s earliest and most high-profile attempts to apply machine learning to drug discovery.Founded in 2013, Be...
ConcertAI CEO Eron Kelly on Big Tech's role in biotech
This week on The Pharma Letter Podcast, we’re joined by Eron Kelly, chief executive of ConcertAI: a company applying artificial intelligence to accelerate oncology research and clinical development.ConcertAI sits at the intersection of ...
How blood cancer treatment is evolving in the Middle East
This week on the Podcast, we are joined by Dr Amr Hanbali.During Blood Cancer Awareness Month, Guy Martin, news editor at The Pharma Letter, sat down with Dr Hanbali to discuss his experiences treating patients with CAR T-cell therapy in...
Nouscom bets on dual vaccine strategy to outsmart cancer
This week on The Pharma Letter Podcast, we’re joined by Marina Udier, chief executive of Nouscom — a biotech company developing cancer vaccines.Founded in 2015, the firm is working on cancer vaccines that use a viral vector platform to t...
Is this a revolution in Alzheimer's?
This week on The Pharma Letter Podcast, we’re joined by Howard Fillit, co-founder and chief science officer at the Alzheimer’s Drug Discovery Foundation (ADDF).As the FDA approval of anti-amyloid drugs like lecanemab and donanemab marks ...
Why Boehringer and GSK are betting on Ochre
This week on The Pharma Letter Podcast, we’re joined by Quin Wills, co-founder and chief scientific officer of UK biotech Ochre Bio.A physician-scientist with a background in genomics and computational biology, Quin has spent much of hi...
.png)
ICON's AI strategy: faster, smarter trials
This week on The Pharma Letter Podcast, we are joined by Tony Clarke, senior VP of IT digital operations at ICON (Nasdaq: ICLR).As a leader in digital transformation within clinical research, Tony has been at the forefront of implementin...
How real-time data could transform clinical trials
In this week’s podcast, we welcome Iddo Peleg, CEO and co-founder of Yonalink, who provides insights into the current and future state of the clinical trial industry. As we move headlong into 2025, a year that appears set to be cha...
.png)
Japanese pharma in the UK
In this episode, we’ll take a look at the role of Japanese pharmaceutical groups in the UK, with Jackie Davis, general manager at Astellas Pharma.Tokyo-headquartered Astellas (TYO: 4503) has developed a strong portfolio in urology, onco...
How can we use AI to program antibodies?
This week, we discuss a novel AI-driven approach to drug development, and its potential to transform the treatment of cancer and autoimmune diseases.We are joined by Yanay Ofran, chief executive and founder of Israel-based Biolojic Desi...
.png)
Breakthroughs in MASH, with 89bio CEO
This week we’re focusing on an area of clinical research that has been of great interest for a number of years, that is NASH, also known as MASH. It’s a high area of unmet medical need, with over 20 million diagnosed cases across E...
.png)
How to develop cancer drugs faster, with Ellipses Pharma
This week we are speaking with the chief executive of British drug development company Ellipses Pharma. Founded in 2018 to create new cancer therapies, the firm is following a unique multimodal approach to clinical development, lev...
CRO sector surges in bio revolution
In the world of outsourced clinical research, ICON is a big fish in a pond full of other increasingly big fish.In this episode of The Pharma Letter Podcast, we chat with the company’s chief commercial officer, George McMillan.Li...
Lilly looks to lead in Alzheimer's
With an Accelerated nod for Aduhelm (aducanumab) and now full approval for Leqembi (lecanemab) in the USA, Biogen (Nasdaq: BIIB) and Eisai (TYO: ...
AAIC preview with Eisai deputy CCO Michael Irizarry
In the runup to the annual meeting of the Alzheimer’s Association, this week we are speaking with Michael Irizarry, deputy chief clinical officer at Eisai US.At the event in July, there will be plenty to discuss, with recent new data fr...
.jpg)
A new way to innovate, from Flagship Pioneering
Set against a backdrop of foundering confidence in biotech stocks, the success of some companies incubated by Massachusetts-based Flagship Pioneering has been remarkable.Flagship has invested billions of dollars getting startups off the...
%20(2).jpg)
Will radical new EU regs hobble industry?
A draft of the European Commission’s ongoing review of pharmaceutical legislation has leaked, prompting a bitterly-worded reaction from drugmakers, which
.jpg)
Galapagos update—with CEO Paul Stoffels
This week on The Pharma Letter Podcast, we are joined by Galapagos (Euronext: GLPG) chief executive Paul Stoffels.After an illustrious career as chief scientific officer at Johnson & Johnson (NYSE: JNJ), Dr Stoffels is ready for a n...
US midterms and beyond: the outlook for pharma
The outcome of the recent midterm elections in the USA surprised many by returning a Democrat-led Senate, preventing Republicans from gaining control of the next Congress.Analysts, having expected a stronger showing for Republicans, put ...
%20(1).jpg)
Focus on rare liver diseases, with Albireo CEO Ron Cooper
*Partnered contentIn Boston, Massachusetts, one company is now making significant headway in the development of an innovative treatment for rare pediatric liver diseases.Led by president and chief executive officer Ron ...
%20(1).jpg)
Inflation Reduction Act: quick take
As President Joe Biden signs the Inflation Reduction Act into law, drugmakers in the USA are poring over the likely impact on drug prices, and how best to
EQRx plots radical disruption on pricing
For years, commentators have observed that drug prices in the USA are significantly higher than elsewhere in the world. Pointing to the high levels of innovation in the USA, a country where new drugs and biologics tend to get launched f...
Can AI find new drugs for metabolic diseases?
Interest in the potential for artificial intelligence to transform different aspects of the drug discovery and development process is at an all-time high.According to industry analyst GlobalData, the number of AI deals in pharma has dou...
A vaccine for Alzheimer's?
With the approval of Aduhelm (aducanumab), the first new Alzheimer’s treatment in decades, people affected by dementia were given new hope that a breakthrough had finally arrived.A year later, the product is yet to gain traction in the ...
Is there a data capture crisis in biotech?
In recent years there has been an explosion of digital tools and platforms in the life sciences industry, designed to improve processes ranging from drug discovery and development, through to registration and commercialization.As with e...